Terpenoids with activity in the Central Nervous System (CNS);Terpenóides com atividade sobre o Sistema Nervoso Central (SNC)

Revista Brasileira de Farmacognosia

Volumn 19, Issue 1 A, 2009, Pages 140-149

  Passos, Carolina S ^a   Arbo, Marcelo D ^a   Rates, Stela M K ^a   Von Poser, Gilsane L ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Central nervous system; Neurotransmitters; Terpenoids

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ABSINTHOL; ARTEMISININ; BORNEOL; CANNABINOID; GINSENOSIDE; LINALOOL; SALVINORIN A; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG; VALEPOTRIATE; VALERENIC ACID;

CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; NEUROTRANSMISSION; NONHUMAN; REVIEW;

EID: 69949095860     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-695X2009000100024     Document Type: Review

References (67)

1. Adsersen A, Gauguin B, Gudiksen L, Jäger AK 2006. Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase inhibitory activity. J Ethnopharmacol 104: 418-422. (Pubitemid 43361700)
2. Albuquerque UP, Hanazaki N 2006. As pesquisas etnodirigidas na descoberta de novos fármacos de interesse médico e farmacêutico: fragilidades e pespectivas. Rev Bras Farmacogn 16(Supl.): 678-689.
3. Amos S, Vhindo BA, Abbah J, Vongtau HO Edmond I, Binda L, Akah PA, Wambebe C, Gamaniel KS 2003. Postsynaptic dopamine (D2)-mediated behavioural effects of high acute doses of artemisinin in rodents. Brain Res Bull 62: 255-260. (Pubitemid 38091713)
4. Arguello PA, Jentsch JD 2004. Cannabinoid CB1 receptormediated impairment of visuospatial attention in the rat. Psychopharmacology 177: 141-150
5. Barbosa-Filho JM, Medeiros KCP, Diniz MFFM, Batista LM, Athayde-Filho PF, Silva MS, Cunha EVL, Almeida JRGS, Quintans-Júnior LJ 2006. Natural products inhibitors of the enzyme acetylcholinesterase. Rev Bras Farmacogn 16: 258-285.
6. Bear MF, Connors BW, Paradiso MA 2002. Neurociências: desvendando o sistema nervoso. Porto Alegre: Artmed.
7. Bos R, Woerdenbag, HJ, Pras N 2002.Determination of valepotriates. J Chromatogr A 967: 131-146.
8. Bosi DC, Hallak JEC, Dursun SM, Deakin JFW, Zuardi AW 2003. Effects of cannabidiol on (s)-ketamineinduced psychopathology in healthy volunteers. J Psychopharmacol 17 (Suppl): A55.
9. Brochet D, Chermat R, DeFeudis FV, Drieu K 1999. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. Gen Pharmacol 33: 249-256. (Pubitemid 29376463)
10. Burkhard PR, Burkhardt K, Haenggeli C-A, Landis T 1999. Plant-induced seizures: reappearance of an old problem. J Neurol 246: 667-670. (Pubitemid 29417847)
11. Butler MS 2004. The role of natural product chemistry in drug discovery. J Nat Prod 67: 2141-2153. (Pubitemid 40092578)
12. Cardoso-Lopes EM, Carreira RC, Agripino DG, Torres LMB, Cordeiro I, Bolzani VS, Dietrich SMC, Young MCM 2008. Screening for antifungal, DNA-damaging and anticholinesterasic activities of Brazilian plants from the Atlantic Rainforest - Ilha do Cardoso State Park. Rev Bras Farmacogn 18 (Supl.): 655-660.
13. Carr MN, Bekku N, Yoshimura H 2006. Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice. Eur J Pharmacol 531: 160-165. (Pubitemid 43202229)
14. Cha HY, Seo JJ, Park JH, Choi KJ, Hong JT, Oh KW 2004. Anxiolytic effects of total saponin fraction from Ginseng radix rubra on the elevated plus-maze model in mice. J Ginseng Res 28: 132-135.
15. Cha HY, Park JH, Hong JT, Yoo HS, Song S, Hwang BY, Eun JS, Oh KH 2005. Anxiolytic-like effects of ginsenosides on the elevated plus maze model in mice. Biol Pharm Bull 28: 1621-1625. (Pubitemid 41324120)
16. Ceccarelli I, Lariviere WR, Fiorenzani P, Sacerdote P, Aloisi AM 2004. Effects of long-term exposure of lemon essential oil odor on behavioral, hormonal and neuronal parameters in male and female rats. Brain Res 1001: 78-86. (Pubitemid 38221530)
17. Datta BK, Datta SK, Chowdhury MM, Khan Th, Kundu JK, Rashid MA, Nahar L, Sarker SD 2004. Analgesic, antiinflamatory and CNS depressant activities of sesquiterpenes and a flavonoid glycoside from Polygonum viscosum. Pharmazie 59: 222-225. (Pubitemid 38391429)
18. De Paris F. Neves G, Salgueiro JB, Quevedo J, Izquierdo I, Rates SMK 2000. Psycopharmacological screening of Pfaffia glomerata Spreng. (Amaranthaceae) in rodents. J Ethnopharmacol 73: 261-269. (Pubitemid 30750509)
19. 3 receptor activity by an effect on the agonist-induced desensitization. Neuropharmacol 46: 192-201.
20. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR 2005. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Mol Brain Res 138: 191-197.
21. Elisabetsky E, Silva Brum, LF, Souza DO 1995. Anticonvulsant properties of linalool on glutamate related seizure. Phytomedicine 6: 113-119. (Pubitemid 129634468)
22. A receptors. Biochem Pharmacol 69: 1101-1111.
23. Grotenhermen F 2005 Cannabinoids. Curr Drug Targets CNS Neurol Disord 4: 507-530.
24. Höld KM, Sirisoma NS, Ikeda T, Narahashi T, Casida JE 2000. α-Thujone (the active component of absinthe): γ-aminobutiric acid type A receptor modulation and metabolic detoxification. Proc Natl Acad Sci USA 97: 3826-3831. (Pubitemid 30226046)
25. Honório KM, Arroio A, Ferreira da Silva AB 2006. Aspectos terapêuticos de compostos da planta Cannabis sativa. Quim Nova 29: 318-325.
26. A receptors. Biosci Biotechnol Biochem 68: 1842-1848.
27. Houghton PJ 1999. The scientific basis for the reputated avtivity of valerian. J Pharm Pharmacol 51: 505-512.
28. Howes M-JR, Houghton PJ 2003. Plants used in Chinese and Indian tradicional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 75: 513-527.
29. John TF, French LG, Erlichman JS 2006. The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 545: 129-133.
30. Kim S, Anh K, Oh TH, Nah SY, Rhim H 2002. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 296: 247-254.
31. Leite MP, Fassin Jr. J, Baziloni EMF, Almeida RN, Mattei R, Leite JR 2008. Behavioral effects of essential oil of Citrus aurantium L. inhalation in rats. Rev Bras Farmacogn 18 (Supl.): 661-666.
32. Leweke FM, Gerth CW, Klosterkotter J 2004. Cannabis-associated psychosis: current status of research. CNS Drugs 18: 895-910. (Pubitemid 39612018)
33. Leweke FM, Koethe D, Gerth CW 2006. Cannabidiol as an antipsychotic: a double-blind, controlled clinical trial on cannabidiol vs amisulpride in acute schizophrenics. 2005 Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society apud: Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.
34. g2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 111: 458-463.
35. Liao B, Newmark H, Zhou R 2002. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 173: 224-234. (Pubitemid 34151374)
36. Lim JH, Wen TC, Matsuda S, Tanaka J, Maeda N, Peng H, Aburaya J, Ishihara K, Sakanaka M 1997. Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci Res 28: 191-200. (Pubitemid 27280919)
37. Maclennan KM, Darlington CL, Smith PF 2002. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 67: 235-257. (Pubitemid 34880132)
38. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ 2006. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83: 109-113.
39. McKeena D 1996. Plant hallucinogens: springboards for psychotherapeutic drug discovery. Behav Brain Res 73: 109-115.
40. Meschler JP, Howlett AC 1999. Thujone exhibits low affinity for cannabinoid receptors but fails to evoke cannabimimetic responses. Pharmacol Biochem Behav 62: 473-480.
41. Mora S, Díaz-Véliz G, Millán R, Lungenstrass H, Quirós S, Coto-Morales T, Hellión-Ibarrola MC 2005. Anxiolytic and antidepressant-like effects of the hydroalcoholic extract from Aloysia polystachya in rats. Pharmacol Biochem Behav 82: 373-378. (Pubitemid 41727949)
42. Moreira FA, Guimaraes FS 2005. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512: 199-205.
43. O'Connor, KA, Roth BL 2005. Screening the receptorome for plant-base psychoactive compounds. Life Sci 78: 506-511.
44. Oh MH, Houghton PJ, Whang WK, Cho JH 2004. Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomed 11: 544-548.
45. 3H]GABA release. Neurochem Res 24: 1373-1378.
46. Park JH, Cha HY, Seo JJ, Hong JT, Han K, Oh KW 2005. Anxiolytic-like effects on ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng. Prog Neuropsychopharmacol Biol Psychiatry 29: 895-900. (Pubitemid 41080109)
47. Peana AT, De Montis MG, Nieddu E, Spano MT, D'Aquila PS, Pippia P 2004a. Profile of spinal and supra-spinal antinociception of (-)-linalool. Eur J Pharmacol 485: 165-174. (Pubitemid 38134411)
48. Peana AT, De Montis MG, Sechi S, Sircana G, D'Aquila PS, Pippia P 2004b. Effects of (-)-linalool in the acute hyperalgesia induced by carrageenan, L-glutamate and prostaglandin E2. Eur J Pharmacol 497: 279-284. (Pubitemid 39164892)
49. Perazzo FF, Carvalho JCT, Rodrigues M, Morais EKL, Maciel MAM 2007. Comparative anti-infammatory and antinociceptive effects of terpenoids and an aqueous extract obtained from Croton cajucara Benth. Rev Bras Farmacogn 17: 521-528.
50. Perazzo FF, Lima LM, Maistro EL, Carvalho JE, Rehder VLG, Carvalho JCT 2008. Effect of Artemisia annua L. leaves essential oil and ethanol extract on behavioral assays. Rev Bras Farmacogn 18: 686-689.
51. Pergentino de Souza D, Farias Nóbrega FF, Almeida RN 2007. Influence of the chirality of (R)-(-)- and (S)-(+)- carvone in the central nervous system: a comparative tudy. Chirality 19: 264-268. (Pubitemid 46659340)
52. Poyares DR, Guilleminault C, Ohayon M, Tufik S 2002. Can valerian improve the sleep insomniacs after benzodiazepine withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 26: 539-545. (Pubitemid 34252948)
53. Prisinzano TE 2005. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78: 527-531.
54. Quintans-Júnior LJ, Almeida JRGS, Lima JT, Nunes XP, Siqueira JS, Oliveira LEG, Almeida RN, Athayde- Filho PF, Barbosa-Filho JM 2008. Plants with anticonvulsant properties - a review. Rev Bras Farmacogn 18 (Supl.): 798-819.
55. Radad K, Gille G, Moldzio R, Saito H, Rausch WD 2004a. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 17: 41-53. (Pubitemid 39158655)
56. +-affected mesencephalic dopaminergic cells. J Neural Transm 111: 37-45.
57. Radad K, Gille G, Liu L, Rausch WD 2006. Use of ginseng in medicine with emphasis in neurodegenerative disorders. J Pharmacol Sci 100: 175-186.
58. Re L, Barocci S, Sonnino S, Mencarelli A, Vivani C, Paolucci G, Scarpantonio A, Mosca E 2000. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res 42: 177-181. (Pubitemid 30662046)
59. Salah SM, Jäger AK 2005. Screening of traditionally used Libanese herbs for neurological activities. J Ethnopharmacol 97: 145-149.
60. Sheffler DJ, Roth BL 2003. Salvinorin A: the 'magic mint' hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24: 107-109.
61. Silva Brum LF, Emanuelli T, Souza DO, Elisabetsky E 2001. Effects of linalool glutamate release and uptake in mouse cortical synaptossomes. Neurochem Res 26: 191-194. (Pubitemid 32692082)
62. Sousa DP, Nóbrega FFF, Claudino FS, Almeida RN, Leite JR, Mattei R 2007. Pharmacological effects of the monoterpene α,β-epoxy-carvone in mice. Rev Bras Farmacogn 17: 170-175.
63. Sousa FCF, Melo CTV, Citó MCO, Félix FHC, Vasconcelos SMM, Fonteles MMF, Barbosa-Filho JM, Viana GSB 2008. Plantas medicinais e seus constituintes bioativos: Uma revisão da bioatividade e potenciais benefícios nos distúrbios da ansiedade em modelos animais. Rev Bras Farmacogn 18: 642-654.
64. Subhan N, Alam MA, Ahmed F, Shahid IJ, Nahar L, Sarker SD 2008. Bioactivity of Excoecaria agallocha. Rev Bras Farmacogn 18: 521-526.
65. Wang GD, Zhuo M 2002. Synergistic enhancement of glutamate-mediated responses by serotonin and forskolin in adult mouse spinal dorsal horn neurons. J Neurophysiol 87: 732-739. (Pubitemid 34670840)
66. Yan F, Roth BL 2004. Salvinorin A: a novel and highly selective κ-opioid receptor agonist. Life Sci 75: 2615-2619. (Pubitemid 39215054)
67. Zuardi AW, Rodrigues JA, Cunha JM 1991. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104: 260-264.